A healthy lifestyle is the cornerstone of prevention. Its promotion is a major task for all healthcare providers with the collaboration of the family and caregivers. It includes intervention in personal behaviour and risk factors (such as lack of physical activity, use of tobacco, unhealthy food habits and overweight), and all interventions aimed at changing lifestyle should be lifelong.
Introduction
Lifestyle is usually based on long-standing behavioural patterns, maintained by the social environment. A healthy lifestyle is the cornerstone of prevention, and should be promoted by all the healthcare providers with the collaboration of the family and caregivers, as also pointed out in the recent European guidelines. 1 In this paper risk factors and goals are summarised (see Table 1 ). Individual and environmental factors impede the ability to adopt a healthy lifestyle, as does complex or confusing advice from caregivers. Lifestyle modification includes intervention in personal behaviour and risk factors (such as lack of physical activity, use of tobacco, unhealthy food habits and overweight), and all interventions aimed at changing lifestyle should be lifelong.
Behaviour change
Friendly and positive interaction enhances an individual's ability to cope with illness and adhere to recommended lifestyle changes ('empowerment'). It is important to explore patients' experiences, thoughts and worries, previous knowledge and circumstances of everyday life. Individualised counselling is the basis for motivation and commitment. Decision-making should be shared between caregivers and patients (also including the individual's spouse and family). 2, 3 Use of the following principles of communication will facilitate treatment and prevention of cardiovascular disease (CVD):
. spend enough time with the individual to create a therapeutic relationship; . acknowledge the individual's personal view of his/ her disease; . encourage expression of worries and anxieties, concerns and self-evaluation of motivation for behaviour change and chances of success; . speak to the individual in his/her own language and be supportive; . ask questions to check that the individual has understood the advice; . acknowledge that changing life-long habits can be difficult and that gradual change is often more permanent than rapid change; . accept that individuals may need support for a long time and that repeated efforts to encourage and maintain lifestyle change may be necessary; . make sure that all health professionals involved provide consistent information.
In addition, caregivers can build on cognitivebehavioural strategies to assess the individual's thoughts, attitudes and beliefs concerning the perceived ability to change behaviour, as well as the environmental context. Behavioural interventions such as 'motivational interviewing' increase motivation and self-efficacy. 4 Combining the knowledge and skills of caregivers (such as physicians, nurses, psychologists, experts in nutrition, cardiac rehabilitation and sports medicine) into multimodal, behavioural interventions can optimise preventive efforts. 2, 5, 6 Multimodal behavioural interventions are especially recommended for individuals at very high risk. 2, 5, 6 These interventions include promoting a healthy lifestyle through behaviour change including nutrition, physical activity, relaxation training, weight management, and smoking cessation programmes for resistant smokers. 5, 6 Physical activity and exercise A sedentary lifestyle is one of the major risk factors for CVD independently of participation in physical activity. 7 Health practitioners should assess the physical activity level in any individual (how many days and minutes per day are spent). They should warn against inactivity, and help add physical activity to daily life. Regular physical activity is related to a reduced risk of all-cause and CVD mortality in healthy individuals, [8] [9] [10] in individuals with coronary risk factors 10 and cardiac patients 11 over a wide age range. Physical activity has a positive effect on many risk factors, including hypertension, low-density lipoprotein (LDL) cholesterol and non-high-density lipoprotein (HDL) cholesterol, body weight and type 2 diabetes mellitus. 9 This applies for both men and women and across a broad range of ages from childhood to the very elderly.
Similar to all other medications, its prescription can be adjusted in terms of frequency, duration and intensity. However, practising physical activity below the lowest recommended levels should be encouraged in individuals unable to meet the minimum or to those who are sedentary and have just started and are recommended gradually to increase the level.
Physical activity sessions should include the following phases: warm-up, conditioning phase (aerobic, muscle strength/resistance and neuromotor exercise) cool-down, and stretching/flexibility.
Aerobic physical activity
Aerobic physical activity is the most studied and recommended modality, with dose-response beneficial effects on prognosis, [12] [13] [14] and includes everyday activity, such as active travel (cycling or walking), heavy household work, gardening, occupational activity and leisure time activity or exercise such as brisk walking, jogging, cycling, swimming. Moderate activity is recommended in secondary prevention. Intensity can be expressed either in absolute or relative terms ( Table 2) . A frequency of at least three to five sessions Non-HDL-cholesterol is a reasonable and practical alternative target because it does not require fasting. Non HDL-cholesterol secondary targets of <2.3 mmol/L (<100 mg/dL) are recommended for very high-risk individuals. b A view was expressed that primary care physicians might prefer a single general LDL-cholesterol goal of 2.5 mmol/L. While accepting the simplicity of this approach and that it could be useful in some settings, there is better scientific support for the three targets matched to the level of risk. c This is the general recommendation for those at very high risk. It should be noted that the evidence for patients with chronic kidney disease is less strong.
per week, but preferably everyday is recommended. It is recommended to accumulate at least 30 minutes per day, five days/week of moderate intensity (i.e. 150 minutes/week). Aerobic interval training and high intensity interval training cannot yet be broadly recommended, until further data on safety and efficacy are available. 15 
Muscle strength/resistance physical activity
This targets the major muscle groups and includes multi-joint or compound movements, such as working with resistance bands, calisthenics exercise using body weight for resistance, carrying heavy loads and heavy gardening. For each exercise session, the suggested prescription is two to three sets of eight to 12 repetitions at the intensity of 60-80% of the individual's one repetition maximum (1 RM; the maximum load that can be lifted one time) at the frequency of least two days a week. This modality enhances functional status, with some evidence of benefit in lipid and blood pressure (BP) control, and a combination of strength and aerobic exercise may improve insulin sensitivity.
Neuromotor physical activity
This includes multifaceted activities such as tai chi and yoga, and recreational activities using paddles or sport balls to challenge hand/eye coordination. For older adults at risk of falls, this exercise helps to maintain or improve balance, motor skills (balance, agility, coordination and gait).
Smoking cessation
Smoking is a lethal addictive disorder. A lifetime smoker has a 50% probability of dying due to smoking, and on average will lose 10 years of life, 17 contrasting with less than three years in severe hypertension and less than one year with mild hypertension. 18 Smoking is an established cause of a plethora of diseases and is responsible for 50% of all avoidable deaths in smokers, half of these due to CVD. The 10-year fatal CVD risk is approximately doubled in smokers. The relative risk (RR) in smokers younger than 50 years is even fivefold higher than in non-smokers. 19 Although the rate of smoking is declining in Europe, it remains very common and is increasing in women, children and the socially disadvantaged. 20 Widening education-related inequalities in smoking cessation rates have been observed in many European countries. In the EUROASPIRE III survey 30% of the participants were smokers up to the time of their coronary event and this had dropped by one half after 1.5 years. The survey also found that evidence-based treatment for smoking cessation was underused. 21 Mechanisms by which tobacco smoking increases risk. Smoking enhances both the development of atherosclerosis and of superimposed thrombotic phenomena. Smoking affects endothelial function, oxidative processes, platelet function, fibrinolysis, inflammation, lipid oxidation and vasomotor function. In experimental studies, several of these effects are fully or partly reversible within a very short time. Plaque formation is not thought to be fully reversible and thus smokers would never be expected to reach the risk level of never-smokers concerning CVD. Nicotine replacement shows no adverse effect on outcomes in patients with cardiac disease, 22 but endothelial function seems to deteriorate. 23 Dosage and type. The risks associated with smoking show a dose-response relationship with no lower limit for deleterious effects. 24 Duration also plays a role, and while cigarette smoking is the most common, all types of smoked tobacco, including low-tar ('mild' or 'light') cigarettes, filter cigarettes, cigars and pipes are harmful. 25 Smoking is deleterious regardless of how it is smoked, including by waterpipe. Tobacco smoke is more harmful when inhaled but smokers who claim not to inhale the smoke (e.g. pipe smokers) are also at increased risk of CVD. Smokeless tobacco is also associated with a small but statistically significant increased risk of myocardial infarction and stroke.
Passive smoking. Passive smoking increases the risk of coronary artery disease (CAD). 26, 27 A smoking spouse or workplace exposure increases CVD risk by an estimated 30%. Major health benefits result from reduced environmental tobacco smoke, with public smoking bans in various different geographical locations leading to significant decreases in myocardial infarction rates.
Smoking cessation. The benefits of smoking cessation have a major evidence base. Some advantages are almost immediate; others take more time. CVD risk in former smokers is in between that of current and never-smokers. Stopping smoking after a myocardial infarction is potentially the most effective of all preventive measures; a systematic review and meta-analysis showed a mortality benefit of 0.64 (95% confidence interval (CI) 0.58-0.71) compared with continuing smokers. 28 The benefit is consistent over sex, duration of follow-up, study site and time period. Significant morbidity reductions occur within the first six months. 29 Randomised trials also support smoking cessation, with the risk of CVD approaching (but never equalling) the risk of never-smokers within 10-15 years.
Professional support can increase the odds of stopping (RR 1.66; 95% CI 1.42-1.94). 30 An impetus for smoking cessation occurs at the time of diagnosis or (invasive) treatment of CVD. Prompting a person to try to quit, brief reiteration of the cardiovascular and other health hazards, and agreeing on a specific plan with a follow-up arrangement are evidence-based interventions. Smoking cessation programmes initiated during hospital admission should continue for a prolonged period after discharge. A smoking history including daily tobacco consumption and degree of addiction (most commonly assessed by the Fagerstro¨m test) 30 should guide the degree of support and pharmacological aid.
In addition to advice and encouragement, nicotine replacement therapy (NRT), varenicline or bupropion should be offered to assist cessation. 31 All forms of NRT (chewing gum, transdermal nicotine patches, nasal spray, inhaler and sublingual tablets) are effective; in a systematic review, the RR for abstinence with NRT versus control was 1.58 (95% CI 1.50-1.66). 32 The use of nicotine patches has been successfully tested, without adverse effects, in patients who have CAD. Clonidine helped people to quit, but causes side effects and is therefore a second line agent. It is not clear whether or not mecamylamine used with NRT helps people to quit. Other treatments did not seem to help. So far, nicotine vaccines are not licensed for use anywhere in the world. 31 Combining two types of NRT is as effective as using varenicline, and helps more people to quit than single types of NRT. 31 E-cigarettes are battery-operated devices that simulate combustible cigarettes by heating nicotine and other chemicals into a vapour that is inhaled. Electronic cigarettes deliver the addictive nicotine without the vast majority of tobacco chemicals, and the European Medicines Agency concluded that electronic cigarettes are less harmful than tobacco. Evidence on the effectiveness of electronic cigarettes is limited, although data from observational and randomised trials suggest that the efficacy of first generation electronic cigarettes is similar to that of transdermal NRT patches 33 or NRT inhalators. 34 These studies and 'real world' data indicate that electronic cigarettes are moderately effective as smoking cessation and harm reduction aids, but that a significant component of that effect is due to the behaviour rather than nicotine delivery. Although the long-term safety of e-cigarettes is unknown, no safety issues are observed in the short term (two years).
Cardioprotective diets
Dietary habits influence cardiovascular risk, either through an effect on risk factors such as cholesterol, BP, body weight and diabetes mellitus, or through other effects. 35 Table 3 summarises the characteristics of a healthy diet.
Most evidence on the relationship between nutrition and CVD is based on observational studies; randomised clinical trials estimating the impact of diet on endpoints are scarce. The impact of diet is studied on three levels: specific nutrients, specific foods/food groups or specific dietary patterns, of which the Mediterranean diet is the most studied.
The nutrients of interest with respect to CVD are fatty acids (which mainly affect lipoprotein levels), minerals (which mainly affect BP), vitamins and fibre.
For the prevention of CVD, the types of fatty acids consumed are more important than the total fat content. The risk of CAD is reduced by 2-3% when 1% of energy intake from saturated fatty acids is replaced by polyunsaturated fatty acids. Polyunsaturated fatty acids lower LDL-cholesterol levels, and to a lesser extent HDL-cholesterol levels, when they replace saturated fatty acids. The trans fatty acids, a subclass of unsaturated fatty acids, have been shown to be especially harmful, due to their unfavourable impact on both total cholesterol (increase) and HDL-cholesterol (decrease). These fatty acids are formed during industrial processing (hardening) of fats, and present for example in margarine and bakery products. A metaanalysis of prospective cohort studies has shown that, on average, a 2-energy-% higher trans fatty acid intake increases CAD risk by 23%. 36 It is recommended to derive less than 1% of total energy intake from trans fatty acids, the less the better.
Meta-analysis estimated that even a modest reduction in sodium intake of 1 g/day reduces systolic BP by 3.1 mmHg in hypertensive patients and 1.6 mmHg in normotensive patients. 37 The DASH trial showed a dose-response relation between sodium reduction and BP reduction. 38 Potassium has favourable effects on BP. The main sources of potassium are fruits and vegetables. An inverse statistically significant association was seen between potassium intake and the risk of incident stroke (risk ratio 0.76, 0.66 to 0.89). 39 Apart from reducing sodium intake, increasing potassium intake contributes to BP lowering.
Many case-control and prospective observational studies have observed inverse associations between levels of vitamins A and E and the risk of CVD. However, intervention trials have failed to confirm these observational studies. This was also the case for the B vitamins (B6, folic acid and B12).
Recent meta-analyses of prospective cohort studies show that a 7 g/day higher intake of total fibre is associated with a 9% lower risk of CAD (RR 0.91; 95% CI 0.87-0.94), 40 and a 10 g/day higher fibre intake is associated with a 16% lower risk of stroke (RR 0.84; 95% CI 0.75-0.94) 41 and a 6% lower risk of diabetes type 2 (RR 0.94; 95% CI 0.91-0.97). 42 
Fruits and vegetables
Prospective cohort studies have shown a protective effect of the consumption of fruits and vegetables on CVD, but randomised controlled trials are scarce. A meta-analysis on cardiovascular mortality reported a decrease of 4% (RR 0.96; 95% CI 0.92-0.99) for each additional serving of fruits (equivalent to 77 g) and vegetables (equivalent to 80 g) per day. 43 A meta-analysis reported a risk reduction for stroke of 11% (RR 0.89; 95% CI 0.83-0.97) for three to five daily fruit and vegetables servings and of 26% (RR 0.74; 95% CI 0.69-0.79) for more than five servings, compared with less than three servings. 44 A meta-analysis on CAD reported a 4% decrease in CAD risk of (RR 0.96; 95% CI 0.93-0.99) for each additional serving of fruits and vegetables per day. 45 Studies suggest that consuming about 30 g (a handful) of nuts per day may reduce the risk of developing heart disease by 30-50% and reduce the risk of death from heart disease by around 20%. This is based on the high proportion of healthy monounsaturated and polyunsaturated fats in nuts, and the low proportion of saturated fats.
Fish
The protective effect of fish on CVD is attributed to the n-3 fatty acid content. Pooled risk estimates from prospective cohort studies show that eating fish at least once a week results in a 16% reduction in the risk of CAD (RR 0.85; 95% CI 0.75-0.95) compared to eating less fish. 46 A recent meta-analysis showed that eating fish two to four times a week reduced the risk of stroke by 6% (RR 0.94; 95% CI 0.90-0.98) compared with eating fish less than once a week. 47 The relationship between fish intake and cardiovascular risk is not linear. Especially in the range of no or very low intake risk is increased. The public health impact of a small increase in fish consumption in the general population is therefore potentially large. Saturated fatty acids to account for <10% of total energy intake, through replacement by polyunsaturated fatty acids Trans unsaturated fatty acids: as little as possible, preferably no intake from processed food, and <1% of total energy intake from natural origin <5 g of salt per day 30-45 g of fibre per day, preferably from wholegrain products 200 g of fruit per day (2-3 servings) 200 g of vegetables per day (2-3 servings) Fish at least twice a week, one of which to be oily fish Consumption of alcoholic beverages should be limited to two glasses per day (20 g/day of alcohol) for men and one glass per day (10 g/day of alcohol) for women
Alcoholic beverages
Drinking three or more alcoholic beverages per day is associated with an elevated CVD risk. Results from epidemiological studies suggest a lower risk with moderate (one to two units per day) alcohol consumption on the occurrence of CVD compared to non-drinkers. This association appears not to be explained by special characteristics of abstainers, 48 although the potential for residual confounding and reverse causality cannot be fully excluded. Moreover, a recent Mendelian randomisation study including analyses from 59 epidemiological studies has shed considerable doubt on any beneficial effect of moderate alcohol consumption, 49 suggesting that the lowest risks for CVD outcomes were in abstainers, and that any amount of alcohol was associated with elevated BP and BMI.
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